About five months ago, I wrote my last article about Bristol-Myers Squibb Company (NYSE: BMY ). And after being a bit more cautious in my previous article, I clearly argued that the stock was a “Buy” at this point and a bargain. InMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitaliza ...